Nektar Therapeutics to Participate in Upcoming Investor Conferences

NKTR 11.06.2024

Full Press ReleaseSEC FilingsOur NKTR Tweets

About Gravity Analytica

Recent News

  • 01.10.2025 - Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis
  • 01.09.2025 - Mayank Mamtani

Recent Filings

  • 01.17.2025 - 5 Annual statement of changes in beneficial ownership of securities
  • 12.26.2024 - 144 Report of proposed sale of securities
  • 12.26.2024 - 4 Statement of changes in beneficial ownership of securities

SAN FRANCISCO,Nov. 6, 2024/PRNewswire/ --Nektar Therapeutics(Nasdaq: NKTR)today announced that the company will be webcasting its participation in the upcoming conferences:

  • UBS Global Healthcare Conferencein Rancho Palos Verdes, CA onWednesday, November 13, 2024at1:15 p.m. Eastern Time/10:15 a.m. Pacific Time– webcast linkhere
  • Piper Sandler 36thAnnual Healthcare Conference inNew York, NYonWednesday, December 4, 2024at1:00 p.m. Eastern Time/4:00 p.m. Pacific Time– webcast linkhere

The presentations will be accessible via the webcast links above as well as on the Investor Events section of the Nektar website:https://ir.nektar.com/events-and-presentations/events. Replays of the presentations will be available for 30 days.

If you would like to request a one-on-one meeting with company management during the conferences, please reach out to your respective bank representative.

AboutNektar Therapeutics

Nektar Therapeuticsis a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Our pipeline also includes a preclinical candidate NKTR-0165, which is a bivalent tumor necrosis factor receptor type II agonist antibody. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered inSan Francisco, California. For further information, visitwww.nektar.comand follow us onLinkedIn.

Contact:

For Investors:

Vivian WuNektar Therapeutics628-895-0661

For Media:

Madelin HawtinLifeSci Communications603-714-2638mhawtin@lifescicomms.com

CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-therapeutics-to-participate-in-upcoming-investor-conferences-302297943.html

SOURCENektar Therapeutics

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com